Palbociclib

Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib is a highly specific inhibitor of cyclindependent kinase 4 (Cdk4) (IC50, 0.011 μmol/L) and Cdk6 (IC50, 0.016 μmol/L), having no activity against a panel of 36 additional protein kinases.

中文名 帕博西林，帕博昔布 外文名Palbociclib 原研企業 美國輝瑞制藥（Pfizer） 藥物類別 吡啶并嘧啶衍生化的CDK抑制劑

Palbociclib的生物活性

Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib is a highly specific inhibitor of cyclindependent kinase 4 (Cdk4) (IC50, 0.011 μmol/L) and Cdk6 (IC50, 0.016 μmol/L), having no activity against a panel of 36 additional protein kinases.

化學信息:

外觀：黃色至灰白色晶狀固體

分子量: 447.53

分子式: C24H29N7O2

CAS號: 571190-30-2

溶劑/溶解度: DMSO

晶型：2種，A和B，均為無水晶體

儲存條件: 參考CoA中推薦的條件進行儲存。